{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:45:14Z","timestamp":1773276314667,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":6342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1111\/j.1538-7836.2005.01460.x","type":"journal-article","created":{"date-parts":[[2005,8,8]],"date-time":"2005-08-08T04:34:38Z","timestamp":1123475678000},"page":"1682-1691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?"],"prefix":"10.1016","volume":"3","author":[{"given":"K.","family":"HIGH","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0010","first-page":"195","article-title":"Using nucleases to stimulate homologous recombination","volume":"262","author":"Carroll","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0015","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2002-03-0823","article-title":"Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high\u2010capacity adenoviral vectors","volume":"101","author":"Chuah","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0020","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1073\/pnas.96.5.2296","article-title":"Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease","volume":"96","author":"Daly","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0025","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","article-title":"Systemic delivery of genes to striated muscles using adeno\u2010associated viral vectors","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0030","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","article-title":"Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV","volume":"94","author":"Herzog","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mthe.2002.0650","article-title":"Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model","volume":"6","author":"Marshall","year":"2002","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35017565","article-title":"Therapeutic haemoglobin synthesis in beta\u2010thalassaemic mice expressing lentivirus\u2010encoded human beta\u2010globin","volume":"406","author":"May","year":"2000","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ng0797-270","article-title":"Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors","volume":"16","author":"Snyder","year":"1997","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0050","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2002-10-3050","article-title":"Neonatal or hepatocyte growth factor\u2010potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B","volume":"101","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0055","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus\u2010mediated gene transfer","volume":"10","author":"Ziegler","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)\u2010X1 disease","volume":"288","author":"Cavazzana\u2010Calvo","year":"2000","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0065","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X\u2010linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein\u2010Bey\u2010Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X\u2010linked severe combined immunodeficiency","volume":"348","author":"Hacein\u2010Bey\u2010Abina","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0075","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2\u2010associated clonal T cell proliferation in two patients after gene therapy for SCID\u2010X1","volume":"302","author":"Hacein\u2010Bey\u2010Abina","year":"2003","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng0501-92","article-title":"Gene therapy restores vision in a canine model of childhood blindness","volume":"28","author":"Acland","year":"2001","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0085","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2004-07-2908","article-title":"Regional intravascular delivery of AAV\u20102\u2010FIX to skeletal muscle achieves long\u2010term correction of hemophilia B in a large animal model","volume":"105","author":"Arruda","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0090","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ymthe.2004.01.015","article-title":"Long\u2010term lowering of plasma cholesterol levels in LDL\u2010receptor\u2010deficient WHHL rabbits by gene therapy","volume":"9","author":"Kankkonen","year":"2004","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0095","doi-asserted-by":"crossref","first-page":"13102","DOI":"10.1073\/pnas.192353499","article-title":"Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs","volume":"99","author":"Ponder","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0100","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno\u2010associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0105","first-page":"335","article-title":"Adenovirus vectors: biology, design, and production","volume":"273","author":"Imperiale","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0110","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved system for helper\u2010dependent adenoviral vector production","volume":"8","author":"Palmer","year":"2003","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0115","first-page":"750","article-title":"Scaling\u2010up production of recombinant AAV vectors for clinical applications","volume":"3","author":"Qu","year":"2000","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0120","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","article-title":"Canine hemophilia B resulting from a point mutation with unusual consequences","volume":"86","author":"Evans","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0125","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00335-003-2290-z","article-title":"A line 1 insertion in the factor IX gene segregates with mild hemophilia B in dogs","volume":"14","author":"Brooks","year":"2003","journal-title":"Mamm Genome"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0037-1613063","article-title":"Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia","volume":"87","author":"Hough","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first\u2010generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/320196a0","article-title":"Cause of the \u2018inhibitor\u2019 phenotype in the haemophilias","volume":"320","author":"Giannelli","year":"1986","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0145","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.V87.6.2612.bloodjournal8762612","article-title":"A genetic view on the etiology of the inhibitor complication","volume":"87","author":"Giannelli","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0150","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX\u2010specific T and B cell responses in muscle\u2010directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle\u2010directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2001-11-0067","article-title":"Dangerous liaisons: the role of \u2018danger\u2019 signals in the immune response to gene therapy","volume":"100","author":"Brown","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood.V97.1.107","article-title":"Systemic delivery of an adenoviral vector encoding canine factor VIII results in short\u2010term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs","volume":"97","author":"Gallo\u2010Penn","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0170","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotype correction of hemophilia B dogs with a factor IX null mutation by liver\u2010directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0175","series-title":"DNA Vaccines","first-page":"227","article-title":"Immune responses in gene transfer for genetic disorders","author":"Sabatino","year":"2003"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0180","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1172\/JCI1880","article-title":"Therapeutic levels of human protein C in rats after retroviral vector\u2010mediated hepatic gene therapy","volume":"101","author":"Cai","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0185","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood.V94.12.3968","article-title":"Adenovirus\u2010mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose\u2010limiting toxicity","volume":"94","author":"Lozier","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0190","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2002-02-0589","article-title":"Sustained high\u2010level expression of human factor IX (hFIX) after liver\u2010targeted delivery of recombinant adeno\u2010associated virus encoding the hFIX gene in rhesus macaques","volume":"100","author":"Nathwani","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0195","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1182\/blood-2004-10-3867","article-title":"Sustained correction of disease in naive and AAV2\u2010pretreated hemophilia B dogs: AAV2\/8 mediated, liver\u2010directed gene therapy","volume":"105","author":"Wang","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0200","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.V89.4.1254","article-title":"Therapeutic levels of functional human factor X in rats after retroviral\u2010mediated hepatic gene therapy","volume":"89","author":"Le","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0205","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long\u2010term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII\u2010deficient mice","volume":"96","author":"Vanden Driessche","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0210","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat Rev Genet"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/4743","article-title":"Long\u2010term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno\u2010associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0220","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX\u2010specific T and B cell responses in muscle\u2010directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0225","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V97.1.130","article-title":"Posttranslational modifications of recombinant myotube\u2010synthesized human factor IX","volume":"97","author":"Arruda","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0230","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat Genet"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0235","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV\u2010mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/7439","article-title":"Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno\u2010associated viral vector","volume":"5","author":"Greelish","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0245","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(03)01141-0","article-title":"Current uses of isolated limb perfusion in the clinic and a model system for new strategies","volume":"4","author":"Eggermont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/bjs.1800831004","article-title":"Thirty\u2010five years of isolated limb perfusion for melanoma: indications and results","volume":"83","author":"Vrouenraets","year":"1996","journal-title":"Br J Surg"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0255","doi-asserted-by":"crossref","first-page":"868a","DOI":"10.1182\/blood.V104.11.3179.3179","article-title":"A novel method of regional intravenous delivery of AAV vector in skeletal muscle results in correction of canine hemophilia B phenotype","volume":"104","author":"Arruda","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0260","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V88.9.3451.bloodjournal8893451","article-title":"A deletion mutation causes hemophilia B in Lhasa Apso dogs","volume":"88","author":"Mauser","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0265","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1055\/s-0037-1614374","article-title":"Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees","volume":"82","author":"Gu","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0270","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"Gregorevic","year":"2004","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0275","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","article-title":"Extrachromosomal recombinant adeno\u2010associated virus vector genomes are primarily responsible for stable liver transduction in vivo","volume":"75","author":"Nakai","year":"2001","journal-title":"J Virol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0280","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.gt.3300680","article-title":"Adeno\u2010associated virus vectors can be efficiently produced without helper virus","volume":"5","author":"Matsushita","year":"1998","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0285","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of high\u2010titer recombinant adeno\u2010associated virus vectors in the absence of helper adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J Virol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/sj.gt.3302539","article-title":"Major role of local immune responses in antibody formation to factor IX in AAV gene transfer","author":"Wang","year":"2005","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0295","article-title":"Systemic protein delivery by muscle gene transfer is limited by a local immune response","author":"Wang","year":"2005","journal-title":"Blood (ePub)"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0300","first-page":"491","article-title":"Viral vectors for gene transfer to striated muscle","volume":"6","author":"Gregorevic","year":"2004","journal-title":"Curr Opin Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0305","series-title":"Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, Minutes of Meeting, National Institutes of Health","year":"2004"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0310","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno\u2010associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/mthe.2000.0031","article-title":"Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV\u2010mediated gene therapy in liver","volume":"1","author":"Wang","year":"2000","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0320","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1525-0016(16)40507-1","article-title":"AAV 8 serotype: total correction of hemophilia A mice and partial correction in dogs with canine FVIII","volume":"7","author":"Sarkar","year":"2003","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0325","doi-asserted-by":"crossref","first-page":"S383","DOI":"10.1016\/j.ymthe.2004.06.940","article-title":"Immune responses to AAV and to factor IX in a phase I study of AAV\u2010mediated, liver\u2010directed gene transfer for hemophilia B","volume":"9","author":"High","year":"2004","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0330","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.ymthe.2004.05.060","article-title":"Duration of immunologically detectable AAV\u20102 capsid in an animal model","volume":"9","author":"Sabatino","year":"2004","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0335","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/414677a","article-title":"Trial halted after gene shows up in semen","volume":"414","author":"Boyce","year":"2001","journal-title":"Nature"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0340","series-title":"Biological Response Modifiers Advisory Committee Issues Pertaining To Inadvertent Germline Transmission of Gene Transfer Vectors, FDA","year":"2002"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.8211118","article-title":"In vivo gene therapy of hemophilia B: sustained partial correction in factor IX\u2010deficient dogs","volume":"262","author":"Kay","year":"1993","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0350","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0092-8674(03)00760-8","article-title":"Targeting survival: integration site selection by retroviruses and LTR\u2010retrotransposons","volume":"115","author":"Bushman","year":"2003","journal-title":"Cell"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0360","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1371\/journal.pbio.0020234","article-title":"Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences","volume":"2","author":"Mitchell","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","article-title":"HIV\u20101 integration in the human genome favors active genes and local hotspots","volume":"110","author":"Schroder","year":"2002","journal-title":"Cell"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0370","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.1083413","article-title":"Transcription start regions in the human genome are favored targets for MLV integration","volume":"300","author":"Wu","year":"2003","journal-title":"Science"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1073\/pnas.94.2.575","article-title":"Characterization of the chicken beta\u2010globin insulator","volume":"94","author":"Chung","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0380","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S1471-4914(02)02318-3","article-title":"The emerging fields of suicide gene therapy and virotherapy","volume":"8","author":"Kirn","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0385","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nbt753","article-title":"Site\u2010specific genomic integration produces therapeutic factor IX levels in mice","volume":"20","author":"Olivares","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0390","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ymthe.2004.06.123","article-title":"Phenotypic correction of a hemophilia B dog following systemic administration of a helper\u2010dependent Ad vector encoding canine coagulation factor IX","volume":"9","author":"Brunetti\u2010Pierri","year":"2004","journal-title":"Mol Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0395","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2003-05-1426","article-title":"Helper\u2010dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A","volume":"103","author":"Brown","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0400","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2003-01-0314","article-title":"A gene\u2010deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia","volume":"102","author":"Ehrhardt","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0405","article-title":"Pre\u2010clinical efficacy and safety studies of a gutless adenovirus vector (MAXADFVIII) for treatment of hemophilia A","author":"Fang","year":"2001","journal-title":"Thromb Haemost Suppl"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0410","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/sj.gt.3301024","article-title":"Persistent expression of canine factor IX in hemophilia B canines","volume":"6","author":"Chao","year":"1999","journal-title":"Gene Ther"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0415","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.20392","article-title":"Effective gene therapy for an inherited CNS disease in a large animal model","volume":"57","author":"Vite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0420","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood-2002-12-3722","article-title":"Treatment of canine cyclic neutropenia by lentivirus\u2010mediated G\u2010CSF delivery","volume":"102","author":"Yanay","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0425","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.192219599","article-title":"The Chapel\u2010Hill hemophilia A dog colony exhibits a factor VIII gene inversion","volume":"99","author":"Lozier","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0038-1651541","article-title":"The development of hemologous (canine\/anti\u2010canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten\u2010year longitudinal study","volume":"69","author":"Tinlin","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2005.01460.x_bb0435","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated factor VII","volume":"113","author":"Margaritis","year":"2004","journal-title":"J Clin Invest"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2005.01460.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622163245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622163245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2005.01460.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:36:38Z","timestamp":1761532598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622163245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S1538783622163245"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01460.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01460.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}